3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
44
Squamous Cell Carcinoma of Head and Neck
19
Breast Neoplasms
18
Lung Neoplasms
17
Colorectal Neoplasms
15
Neoplasms
12
Neoplasm Metastasis
12
Head and Neck Neoplasms
12
Ovarian Neoplasms
11
Small Cell Lung Carcinoma
9
Recurrence
9
Sarcoma
8
Pancreatic Neoplasms
8
Prostatic Neoplasms
7
Advanced Solid Tumors
7
Urinary Bladder Neoplasms
6
Triple Negative Breast Neoplasms
6
Melanoma
6
Lymphoma, Large B-Cell, Diffuse
6
Diabetes Mellitus, Insulin-Dependent, 12
6
Uterine Cervical Neoplasms
5
Carcinoma, Renal Cell
5
Carcinoma, Hepatocellular
5
Biliary Tract Neoplasms
5
Mesothelioma, Malignant
4
Lymphoma, Follicular
4
Lymphoma
4
Fallopian Tube Neoplasms
4
Esophageal Neoplasms
4
Cholangiocarcinoma
4
Interventions
dacetuzumab
6
blinatumomab
6
Rituximab
4
Epoetin Alfa
4
Lenalidomide
3
Dexamethasone
3
Darbepoetin alfa
3
Cyclophosphamide
3
Bortezomib
3
Therapeutics
2
Everolimus
2
Early Intervention, Educational
2
Alemtuzumab
2
venetoclax
1
vandetanib
1
tirbanibulin
1
tetulomab tetraxetan lu-177
1
ponatinib
1
plerixafor
1
pembrolizumab
1
pegaspargase
1
isatuximab
1
imetelstat
1
ibrutinib
1
fludarabine
1
ficlatuzumab
1
ferrous sulfate
1
ferric gluconate
1
ferric carboxymaltose
1
durvalumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Lymphoproliferative Disorders
×
durvalumab
×
Clear all
NCT02733042
2023-11-18
FUSION NHL 001
Celgene
Phase 1/2
Completed
106 enrolled
48 charts